
    
      A Phase I, Randomized, Open-label, Single-center Study to Assess the Pharmacokinetics of
      Vandetanib (CAPRELSA) in Healthy Subjects when a Single Oral Dose of Vandetanib 300 mg is
      Administered Alone and in Combination with Omeprazole or Ranitidine
    
  